TITLE

News Briefs

PUB. DATE
January 2010
SOURCE
American Journal of Health-System Pharmacy;1/1/2010, Vol. 67 Issue 1, p13
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to pharmaceutical industry in the U.S. The Congress asks the Food and Drug Administration (FDA) to report on brand and generic antiepileptic drug-related adverse events and seizures. It announces the retirement of Kaiser Permanente vice president for pharmacy strategy and operations Albert L. Carver in November 2009.
ACCESSION #
47426207

 

Related Articles

  • Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs. Bohn, J; Kortepeter, C; Muñoz, M; Simms, K; Montenegro, S; Pan, G Dal // Clinical Pharmacology & Therapeutics;May2015, Vol. 97 Issue 5, p508 

    Spontaneous adverse event reports constitute an important source of information on previously unknown adverse reactions to marketed medicines. However, the dynamics of such reporting following generic introduction are poorly understood. Using adverse event reports on five antiepileptic drugs...

  • THE REST OF THE CLASS OF '97.  // Modern Healthcare;9/17/2007 Supplement, Vol. 37, p35 

    A list of healthcare executives for the Up & Comers Class of 1997 is presented, including Laurence Abramson of Huron Consulting Group, Barry Arbuckle of MemorialCare Medical Centers, and Corwin Harper of Kaiser Permanente.

  • Out with the new, in with the old. Garber, Alan J. // Endocrine Today;Jan2012, Vol. 10 Issue 1, p7 

    The author reflects on a continuation of trends toward increasing emphasis on drug safety by the U.S. Food and Drug Administration (FDA) in which the potential for much more frequent untoward events for agents under review is being overlooked.

  • Epilepsy Update.  // PharmaWatch: CNS;Sep2010, Vol. 9 Issue 9, p7 

    The article offers news briefs on epilepsy in the U.S. The Food and Drug Administration (FDA) has accepted a new drug application (NDA) submitted by Eisai Inc., a U.S. subsidiary of Eisai Co. Ltd., for a new oral suspension of 40 milligram/milliliter strength formulation of antiepileptic agent...

  • How to Report an Adverse Event to MedWatch.  // Pharmacy Today;Apr2008, Vol. 14 Issue 4, p28 

    The article offers information about the procedures on how to properly report an adverse event to MedWatch Surveillance System of the Food and Drug Administration (FDA) in the U.S. The first step is identify if the event to be reported is serious, clinically important, and has used errors...

  • Research and Clinical Trials.  // Mayo Clinic Guide to Living with a Spinal Cord Injury: Moving Ah;2009, p211 

    The article offers information on research and clinical trials, and benefits and risk of research studies. It mentions that the U.S. Food and Drug Administration (FDA) is committed to protect people in participating trials in the country and the clinical research trials are registered at...

  • Appendix I: Objectives, Scope, and Methodology.  // GAO Reports;3/18/2013, p47 

    An appendix is presented of the objectives, scope and methodology of a U.S. Government Accountability Office (GAO) report on the number of adverse event reports (AER) received by the U.S. Food and Drug Administration (FDA) since 2008.

  • FDA to Silence 'Noise' from too Many Adverse Events. Serebrov, Mari // BioWorld International;3/30/2011, Vol. 16 Issue 13, p3 

    The article reports that the U.S. Food and Drug Administration (FDA) has set new safety reporting requirements for investigational new drugs (INDs) and biologics to lessen the noise from overreporting of individual serious adverse events in clinical trials. The goal of the agency is to make the...

  • Biclustering of Adverse Drug Events in the FDA's Spontaneous Reporting System. Harpaz, R.; Perez, H.; Chase, H. S.; Rabadan, R.; Hripcsak, G.; Friedman, C. // Clinical Pharmacology & Therapeutics;Feb2011, Vol. 89 Issue 2, p243 

    In this article, we present a new pharmacovigilance data mining technique based on the biclustering paradigm, which is designed to identify drug groups that share a common set of adverse events (AEs) in the spontaneous reporting system (SRS) of the US Food and Drug Administration (FDA). A...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics